Functional Characterization of Diacylglycerol Lipases in Mammalian Physiology
二酰甘油脂肪酶在哺乳动物生理学中的功能表征
基本信息
- 批准号:8701001
- 负责人:
- 金额:$ 12.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-15 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:1,2-diacylglycerol2-arachidonylglycerolAddressAdipose tissueAdoptive Cell TransfersAdverse effectsAnabolismAnimal ModelAnimalsAntidiabetic DrugsBehavioralBiochemicalBiological AssayBody TemperatureBody WeightCNR1 geneCaloriesCarbon DioxideChemicalsChemotaxisChronicClinicalDevelopmentDietDiglyceridesDiseaseEatingEicosanoidsEndocannabinoidsEnergy MetabolismEnzyme Inhibitor DrugsEnzyme InhibitorsEnzymesEthanolaminesFatty acid glycerol estersFlow CytometryG-Protein-Coupled ReceptorsGeneticGoalsHealthHeatingHomeostasisHydrolaseInflammationInflammatoryInflammatory ResponseK-Series Research Career ProgramsKnock-outKnockout MiceLabelLeadLipidsMarijuanaMeasurementMeasuresMediatingMentorsMetabolicMetabolic DiseasesMetabolic PathwayMetabolic syndromeMetabolismMonitorMonoacylglycerol LipasesMusNeuraxisNeuronsNon-Insulin-Dependent Diabetes MellitusObesityObesity associated diseaseOrganismOxygenPainPathway interactionsPeripheralPeritoneal MacrophagesPharmaceutical PreparationsPhasePhenotypePhysiologicalPhysiologyPre-Clinical ModelProcessProductionProtein IsoformsProteomicsRegulationSerine HydrolaseSignal PathwaySignal TransductionSignaling MoleculeSiteSynthesis ChemistrySystemTestingTetrahydrocannabinolTherapeutic EffectTissuesTrainingTransgenic Miceanandamidebalance testingcannabinoid receptorendogenous cannabinoid systemenergy balancefeedingin vivoinhibitor/antagonistinnovationinsightinsulin sensitivitylipoprotein lipasemacrophagemetabolomicsmonocytemouse modelnovel therapeuticsoverexpressionpreventrespiratorysmall molecule
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this K99/R00 career development award proposal is to integrate innovate chemical probes, including in vivo-active small-molecule inhibitors and specialized chemoproteomic assays, with well- established genetic knockout and behavioral mouse models to obtain a global view of the pathophysiological consequence of disrupting 2-arachidonoylglycerol (2-AG) biosynthesis in mouse models of obesity and inflammation. The endogenous cannabinoid (endocannabinoid) 2-AG is a lipid transmitter that activates the G- protein-coupled receptors CB1 and CB2, which are also targets for the psychoactive ingredient in marijuana, 9-tetrahydrocannabinol. The importance of the endocannabinoid system in obesity-associated metabolic disorders is highlighted by the clinical activity of CB1 antagonists as anti-obesity and anti-diabetic drugs. Complementary studies in preclinical models have since shown that many of the beneficial effects are due to blocking CB1 receptors at peripheral sites. These studies highlight the need for a deeper understanding of the central and/or peripheral contributions of the endocannabinoid system in regulating energy homeostasis as well as obesity-related disease states. 2-AG biosynthesis in vivo is differentially regulated by two sequence- related enzymes, diacylglycerol lipase-alpha and beta (DAGL alpha and DAGL beta, respectively), providing an experimental (and, eventually translational) opportunity to uncouple central and peripheral endocannabinoid signaling through selective inactivation of DAGL isoforms. This proposal will test the hypothesis that DAGL alpha and DAGL beta biosynthesize 2-AG involved in energy homeostasis and perform complementary functions in energy balance through regulation of CB1-dependent signaling at anatomically-distinct sites. The specific aims are to 1) measure energy homeostasis parameters and body mass composition in vivo in DAGL-disrupted mice 2) measure adipose tissue macrophage accumulation in DAGL-disrupted mice and 3) Determine the physiological effects of inactivating DAGLs in the development and progression of metabolic syndrome. Our preliminary studies show that DAGL alpha display a lean phenotype despite increased food intake, providing evidence of altered energy balance upon central and/or peripheral disruption of 2-AG biosynthesis. Our preliminary studies also show the feasibility of using DAGL-selective inhibitors to uncouple central and peripheral 2-AG signaling pathways in vivo. The candidate aims to combine previous training in chemoproteomics, synthetic chemistry, and quantitative proteomics and metabolomics with new mentored training in mouse models of metabolism and inflammation including non-invasive measurements of metabolic parameters governing energy homeostasis and body mass composition as well as in vivo tracking of adipose tissue macrophage accumulation using adoptive cell transfer and flow cytometry.
描述(由申请人提供):该 K99/R00 职业发展奖提案的总体目标是将创新的化学探针(包括体内活性小分子抑制剂和专门的化学蛋白质组检测)与成熟的基因敲除和行为小鼠模型相结合获得对肥胖和炎症小鼠模型中 2-花生四烯酰甘油 (2-AG) 生物合成破坏的病理生理学后果的全面了解。内源性大麻素 (endocannabinoid) 2-AG 是一种脂质递质,可激活 G 蛋白偶联受体 CB1 和 CB2,这也是大麻中精神活性成分 9-四氢大麻酚的目标。 CB1拮抗剂作为抗肥胖和抗糖尿病药物的临床活性凸显了内源性大麻素系统在肥胖相关代谢紊乱中的重要性。此后,临床前模型的补充研究表明,许多有益效果是由于阻断外周部位的 CB1 受体而产生的。这些研究强调需要更深入地了解内源性大麻素系统在调节能量稳态以及肥胖相关疾病状态中的中枢和/或外周贡献。体内 2-AG 生物合成受到两种序列相关酶二酰甘油脂肪酶-α 和 β(分别为 DAGL α 和 DAGL β)的差异调节,提供了一个实验(最终是翻译)机会,通过DAGL 同种型的选择性失活。该提案将测试以下假设:DAGL α 和 DAGL β 生物合成参与能量稳态的 2-AG,并通过调节解剖学上不同位点的 CB1 依赖性信号传导在能量平衡中发挥互补功能。具体目标是 1) 测量 DAGL 破坏小鼠的体内能量稳态参数和体重组成 2) 测量 DAGL 破坏小鼠的脂肪组织巨噬细胞积累 3) 确定 DAGL 失活对发育和进展的生理影响代谢综合征。我们的初步研究表明,尽管食物摄入量增加,但 DAGL α 显示出瘦表型,这提供了 2-AG 生物合成中枢和/或外周破坏后能量平衡改变的证据。我们的初步研究还表明使用 DAGL 选择性抑制剂在体内解偶联中枢和外周 2-AG 信号通路的可行性。该候选人的目标是将之前的化学蛋白质组学、合成化学、定量蛋白质组学和代谢组学培训与小鼠代谢和炎症模型的新指导培训相结合,包括控制能量稳态和体重组成的代谢参数的非侵入性测量以及体内跟踪使用过继细胞转移和流式细胞术检测脂肪组织巨噬细胞的积累。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons.
通过比较化学蛋白质组学鉴定的高选择性、可逆抑制剂可调节神经元中的二酰基甘油脂肪酶活性。
- DOI:10.1021/jacs.5b04883
- 发表时间:2015-07-15
- 期刊:
- 影响因子:15
- 作者:Baggelaar MP;Chameau PJ;Kantae V;Hummel J;Hsu KL;Janssen F;van der Wel T;Soethoudt M;Deng H;den Dulk H;Allarà M;Florea BI;Di Marzo V;Wadman WJ;Kruse CG;Overkleeft HS;Hankemeier T;Werkman TR;Cravatt BF;van der Stelt M
- 通讯作者:van der Stelt M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ku-Lung Hsu其他文献
Ku-Lung Hsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ku-Lung Hsu', 18)}}的其他基金
Chemical proteomic investigation of lipid kinase specificity and druggability
脂质激酶特异性和成药性的化学蛋白质组学研究
- 批准号:
10660099 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别:
Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
- 批准号:
10538607 - 财政年份:2022
- 资助金额:
$ 12.83万 - 项目类别:
Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
- 批准号:
10341499 - 财政年份:2022
- 资助金额:
$ 12.83万 - 项目类别:
Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
- 批准号:
10580475 - 财政年份:2022
- 资助金额:
$ 12.83万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
9398439 - 财政年份:2017
- 资助金额:
$ 12.83万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
9980632 - 财政年份:2017
- 资助金额:
$ 12.83万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
10198879 - 财政年份:2017
- 资助金额:
$ 12.83万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
10400420 - 财政年份:2017
- 资助金额:
$ 12.83万 - 项目类别:
Functional Characterization of Diacylglycerol Lipases in Mammalian Physiology
二酰甘油脂肪酶在哺乳动物生理学中的功能表征
- 批准号:
9109601 - 财政年份:2015
- 资助金额:
$ 12.83万 - 项目类别:
相似海外基金
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
双脂肪酸酰胺水解酶 (FAAH)/单酰基甘油脂肪酶 (MAGL) 抑制剂,用于治疗大麻使用障碍 (CUD)。
- 批准号:
10577008 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别:
Role of CB1R expressed in the prefrontal cortex in the control of locomotion
前额皮质表达的 CB1R 在运动控制中的作用
- 批准号:
10590320 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别:
Mechanism and Therapeutic Potential of CBD to Repair Blood-Brain Barrier Dysfunction in Epilepsy
CBD修复癫痫血脑屏障功能障碍的机制和治疗潜力
- 批准号:
10644405 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别:
Differential control of 2-AG’s activity at CB1R by ABHD6 and MAGL
ABHD6 和 MAGL 对 CB1R 上 2-AG 活性的差异控制
- 批准号:
10664172 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别:
Activity-dependent endocannabinoid control in epilepsy
癫痫的活动依赖性内源性大麻素控制
- 批准号:
10639147 - 财政年份:2023
- 资助金额:
$ 12.83万 - 项目类别: